Intellia Therapeutics, Inc. (NTLA) company profile
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
About Intellia Therapeutics
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Intellia Therapeutics is a biopharmaceutical company that develops treatments utilizing CRISPR gene editing, lipid nanoparticles, and oligonucleotide technologies to address severe genetic diseases. Its lead investigational product candidates are lonvoguran ziclumeran, designed for hereditary angioedema, and nexiguran ziclumeran, developed for transthyretin amyloidosis. Both therapies are designed as one-time intravenous infusions. The company also develops preclinical and clinical-stage programs in cellular therapies, including universal CAR-T cell treatments. Its therapies target individuals diagnosed with rare and life-threatening conditions, while the business works alongside healthcare prescribers, clinical institutions, and pharmaceutical collaboration partners such as Regeneron.
Operationally, the company conducts international Phase 3 clinical trials, including studies that have enrolled dozens to hundreds of patients across multiple trial sites. Its development activities and commercial infrastructure focus primarily on the United States, alongside regulatory engagements in the European Union and the United Kingdom. The provided text does not identify the location of the company’s corporate headquarters.
Summary of the business section of Intellia Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Intellia Therapeutics, Inc.
- Founded
- 2014
- Headquarters
- Cambridge, MA
- Address
- 400 Technology Square, Suite 100
- Phone
- (857) 285-6200
- Website
- intelliatx.com
- Employees
- 377, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- NTLA
- Exchange
- Nasdaq
- IPO date
- May 6, 2016
- Shares outstanding
- 140M, Jul 31, 2026
- Public float
- $869.49M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1652130
- CUSIP
- 45826J105
- ISIN
- US45826J1051
- FIGI
- BBG007KC7PB0
- Share class FIGI
- BBG007KC7PC9
- LEI
- 5493002T5BCPE5DZC723
- EIN
- 36-4785571
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John M. Leonard | President and CEO, Director | 1,196,479 |
| Jing L. Marantz | EVP, Chief Medical Officer | 199,822 |
| Michael P. Dube | VP, Chief Accounting Officer | 65,022 |
| Edward J. Dulac III | EVP, Chief Financial Officer | 148,175 |
| Birgit C. Schultes | EVP, Chief Scientific Officer | 137,733 |
| James Basta | EVP, General Counsel | 156,794 |
| David Lebwohl | EVP, Chief Medical Officer | 131,192 |
| Eliana Clark | EVP, Chief Technical Officer | 93,864 |
| Derek Hicks | EVP, Chief Business Officer | 59,878 |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | 77,388 |
| Brian Goff | Director | 32,609 |
| Muna Bhanji | Director | 36,403 |
| Georgia Keresty | Director | 41,083 |
| Fred E. Cohen | Director | 216,653 |
| Frank Verwiel | Director | 35,148 |
| Jesse Goodman | Director | 33,559 |
| William J. Chase | Director | 143,893 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.06M | $3.24M | $1.93M | $17 | $187 |
| FY2024 | $15.33M | $353.49K | $4.74M | $21 | $154 |
| FY2023 | $11.66M | $8.32M | $4.06M | $56 | $119 |
| FY2022 | $10.10M | -$14.07M | $3.92M | $64 | $82 |
| FY2021 | $9.77M | $37.78M | $6.99M | $217 | $122 |
| FY2020 | $3.64M | $19.28M | $1.76M | $371 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| John M. Leonard President, Chief Executive Officer | $708.00K | $529.23K | $2.44M | $1.36M | $26.43K | $5.06M | -67% |
| Edward J. Dulac III Executive Vice President, Chief Financial Officer and Treasurer | $526.00K | $271.00K | $848.18K | $466.61K | $56.72K | $2.17M | -68% |
| James Basta Executive Vice President, General Counsel and Corporate Secretary | $494.00K | $227.24K | $718.80K | $395.43K | $11.13K | $1.85M | -62% |
| David Lebwohl Executive Vice President, Chief Medical Officer | $536.00K | $234.23K | $776.30K | $427.06K | $11.13K | $1.98M | -64% |
| Birgit Schultes Executive Vice President, Chief Scientific Officer | $475.00K | $207.58K | $675.67K | $371.70K | $10.14K | $1.74M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 6, 2016
- Offer price
- $18.00
- Securities offered
- 6,000,000
- Gross proceeds
- $108.00M
- Exchange
- Nasdaq
- First trading day
- May 6, 2016
- First-day close
- $22.10+22.8%
- Lock-up ends (est.)
- Nov 2, 2016
“The initial public offering price of our common stock is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 13, 2026, we had 377 full-time employees, 263 of whom were primarily engaged in research and development activities and 106 of whom have an M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 6, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| May 5, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?